Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 26;8:685362. doi: 10.3389/fmolb.2021.685362

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhou, Lu, Huang and Lin.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Taurine supplementation preserved the myotube differentiation ability of C2C12 myoblasts. (A, B) Expression of MyoD1, myogenin, AKT1, phospho-AKT1 (ser473), and MHC in the three groups of C2C12 myoblasts (n = 8). (C) Representative morphological images of normal control (NOR) myotubes, cisplatin-treated (CIS) myotubes, and taurine-supplemented (TAU) myotubes (20×). Scale bar, 100 µm. (D) Relative myotube area. All experiments were conducted on three separate occasions (n = 3); 4–5 morphological images per condition in duplicate were analyzed for each occasion. The total area of myotubes was normalized to nuclear numbers.